0000000000519251

AUTHOR

Alice Bonura

showing 2 related works from this author

An uncommon presentation of eosinophilic granulomatosis with polyangiitis: a case report

2013

Introduction Eosinophilic granulomatosis with polyangiitis is a rare and potentially fatal disease if not readily diagnosed. Cerebral involvement is extremely rare and clinical presentation as hemorrhagic stroke is even rarer. Case presentation A 58-year-old Caucasian man was admitted to our medical unit because of a computed tomography-diagnosed hemorrhagic stroke with right-sided hemiparesis and fever. A chest computed tomography scan also revealed multiple bilateral pulmonary infiltrates; coronary artery, and carotid and left vertebral artery calcifications were also observed. Empiric antimicrobial therapy with cephalosporins was promptly undertaken; low-molecular-weight heparin was intr…

MalePathologymedicine.medical_specialtyChurg-Strauss polyangiitisSettore MED/09 - Medicina Internaeosinophilic granulomatosiCase ReportSelf MedicationChurg-Strauss SyndromeCoronary AngiographyAdrenal Cortex HormonesEosinophilicMedicineHumansChurg–Strauss syndromeCorticosteroidsLeukocytosisSelf-medicationStrokeLungAnti-neutrophil cytoplasmic antibodyMedicine(all)medicine.diagnostic_testbusiness.industryEosinophilic granulomatosis with polyangiitisGeneral MedicineCerebral InfarctionMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseCoronary arteriesStrokemedicine.anatomical_structureAngiographymedicine.symptombusinessGranulomatosis with polyangiitisImmunosuppressive AgentsSystemic vasculitis
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct